Antigen-specific immunotherapy with thyrotropin receptor peptides in Grave's Hyperthyroidism: a Phase I study
Mary Ann Liebert
This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Graves' disease is one of the most common autoimmune conditions, but treatment remains imperfect. This study explores the first-in-human use of antigen-specific immunotherapy with a combination of two thyrotropin receptor (TSHR) peptides (termed ATX-GD-59) in Graves' hyperthyroidism.
Pearce SHS [et al]. Antigen-specific immunotherapy with thyrotropin receptor peptides in Grave's Hyperthyroidism: a Phase I study.Thyroid. 2019 Jul;29(7):1003-1011
This article is freely available via Open Access. Click on the Publisher's URL to access the full-text via the publisher's site.